- Home
- BUUU vs IMMX Comparison
BUUU vs IMMX Comparison
Compare BUUU & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUUU
- IMMX
- Stock Information
- Founded
- BUUU 2017
- IMMX 2014
- Country
- BUUU Hong Kong
- IMMX United States
- Employees
- BUUU N/A
- IMMX N/A
- Industry
- BUUU Services-Misc. Amusement & Recreation
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BUUU Consumer Discretionary
- IMMX Health Care
- Exchange
- BUUU Nasdaq
- IMMX Nasdaq
- Market Cap
- BUUU 68.1M
- IMMX 65.5M
- IPO Year
- BUUU 2025
- IMMX 2021
- Fundamental
- Price
- BUUU $8.54
- IMMX $2.06
- Analyst Decision
- BUUU
- IMMX Strong Buy
- Analyst Count
- BUUU 0
- IMMX 1
- Target Price
- BUUU N/A
- IMMX $8.00
- AVG Volume (30 Days)
- BUUU 37.3K
- IMMX 171.8K
- Earning Date
- BUUU 01-01-0001
- IMMX 11-11-2025
- Dividend Yield
- BUUU N/A
- IMMX N/A
- EPS Growth
- BUUU N/A
- IMMX N/A
- EPS
- BUUU 0.04
- IMMX N/A
- Revenue
- BUUU $5,754,120.00
- IMMX N/A
- Revenue This Year
- BUUU N/A
- IMMX N/A
- Revenue Next Year
- BUUU N/A
- IMMX N/A
- P/E Ratio
- BUUU $221.56
- IMMX N/A
- Revenue Growth
- BUUU 64.23
- IMMX N/A
- 52 Week Low
- BUUU $3.67
- IMMX $1.26
- 52 Week High
- BUUU $9.50
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- BUUU N/A
- IMMX 44.33
- Support Level
- BUUU N/A
- IMMX $1.98
- Resistance Level
- BUUU N/A
- IMMX $2.15
- Average True Range (ATR)
- BUUU 0.00
- IMMX 0.13
- MACD
- BUUU 0.00
- IMMX 0.01
- Stochastic Oscillator
- BUUU 0.00
- IMMX 34.29
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.